Nurix Therapeutics, Inc. NRIX Other Current Liabilities
Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s other current liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported other current liabilities of $4.12M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s other current liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s other current liabilities decreased by 40.6% year-over-year, from $6.94M to $4.12M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s other current liabilities?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s other current liabilities has grown at a 29.2% compound annual growth rate (CAGR), from $6.22M to $17.31M.